Opko Partners with Bristol-Myers Squibb on Alzheimer's Blood Test

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.